Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;233(3):2058-2066.
doi: 10.1002/jcp.25890. Epub 2017 May 23.

Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

Afsane Bahrami  1 , Seyed Mahdi Hassanian  2   3 , Soodabeh ShahidSales  4 , Zahra Farjami  1 , Malihe Hasanzadeh  5 , Kazem Anvari  4 , Amir Aledavood  4 , Mina Maftouh  2 , Gordon A Ferns  6 , Majid Khazaei  7 , Amir Avan  2   4
Affiliations
Review

Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer

Afsane Bahrami et al. J Cell Physiol. 2018 Mar.

Abstract

The V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently dysregulated in colorectal cancer (CRC). It is involved in the modulation of several downstream effectors, that include: Raf/Mek/Erk, PI3K/Akt, RalGDS/p38MAPK, and Rac/Rho, and thereby influences tumorigenesis, the invasive behaviors of tumor cell, and resistance to therapy. There is growing evidence exploring the use of drugs that target these pathways in the treatment of CRC. Cetuximab has been approved for CRC patients without a KRAS mutation, or for EGFR-expressing metastatic CRC, although some of the patients have a mutation of KRAS and NRAS. This review summarizes the recent knowledge about the therapeutic potential of targeting RAS with particular emphasis on recent preclinical and clinical studies in treatment of CRC.

Keywords: KRAS; cetuximab; colorectal cancer; novel anticancer agent.

PubMed Disclaimer

MeSH terms